Ocular Therapeutix (NASDAQ:OCUL) is set to announce its earnings results after the market closes on Wednesday, February 28th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.
Shares of Ocular Therapeutix (NASDAQ OCUL) opened at $4.79 on Wednesday. Ocular Therapeutix has a one year low of $3.30 and a one year high of $11.79. The firm has a market cap of $173.20, a PE ratio of -2.11 and a beta of 1.53. The company has a quick ratio of 4.78, a current ratio of 4.79 and a debt-to-equity ratio of 0.39.
A number of analysts recently weighed in on OCUL shares. Zacks Investment Research lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, November 8th. ValuEngine upgraded shares of Ocular Therapeutix from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Finally, BTIG Research upgraded shares of Ocular Therapeutix from a “neutral” rating to a “buy” rating in a report on Friday, January 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.67.
In other news, insider Daniel M. Bollag bought 24,700 shares of Ocular Therapeutix stock in a transaction on Wednesday, December 6th. The stock was acquired at an average cost of $3.93 per share, for a total transaction of $97,071.00. Following the completion of the acquisition, the insider now owns 24,700 shares of the company’s stock, valued at approximately $97,071. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Antony C. Mattessich bought 21,000 shares of Ocular Therapeutix stock in a transaction on Tuesday, December 12th. The stock was purchased at an average price of $4.29 per share, with a total value of $90,090.00. Following the completion of the acquisition, the insider now directly owns 21,000 shares of the company’s stock, valued at approximately $90,090. The disclosure for this purchase can be found here. Insiders acquired 50,500 shares of company stock valued at $206,361 over the last quarter. 26.10% of the stock is currently owned by corporate insiders.
A hedge fund recently raised its stake in Ocular Therapeutix stock. The Manufacturers Life Insurance Company boosted its position in Ocular Therapeutix Inc (NASDAQ:OCUL) by 24.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,739 shares of the biopharmaceutical company’s stock after purchasing an additional 3,650 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.06% of Ocular Therapeutix worth $174,000 at the end of the most recent reporting period. 37.08% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Ocular Therapeutix (OCUL) to Release Earnings on Wednesday” was posted by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.thestockobserver.com/2018/02/21/ocular-therapeutix-ocul-to-release-earnings-on-wednesday.html.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.